Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice

Diabetes and Metabolism

Volumn 41, Issue 1, 2015, Pages 82-90

  Ye, X ^a   Qi, J ^a   Wu, Y ^a   Yu, D ^a   Xu, P ^a   Li, S ^a   Zhu, S ^b   Wu, Q ^a   Ren, G ^a   Li, D ^a  

^a NORTHEAST AGRICULTURAL UNIVERSITY   (China)

^b JIANGNAN UNIVERSITY   (China)

Author keywords

Diabetes; FGF 21; Hypoglycaemic effect; Insulin glargine; PEGylation

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN GLARGINE; ANTIDIABETIC AGENT; FIBROBLAST GROWTH FACTOR; GLARGINE; GLUCOSE BLOOD LEVEL; LONG ACTING INSULIN; MACROGOL DERIVATIVE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; INSULIN RESISTANCE; LIVER FUNCTION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ANIMAL; BLOOD; C57BL MOUSE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; EATING; LIPID METABOLISM; LIVER; METABOLISM; TRANSGENIC MOUSE;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; EATING; FIBROBLAST GROWTH FACTORS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; POLYETHYLENE GLYCOLS;

EID: 84921850526     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2014.09.001     Document Type: Article

References (46)

1. Nishimura T., Nakatake Y., Konishi M., Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000, 1492:203-206.
2. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005, 115:1627-1635.
3. Wente W., Efanov A.M., Brenner M., Kharitonenkov A., Köster A., Sandusky G.E., et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006, 55:2470-2478.
4. Huang X., Yu C., Jin C., Yang C., Xie R., Cao D., et al. Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog 2006, 45:934-942.
5. Jiang Y., Liu M., Ren G., Wang W., Liu X., Li D. Cloning, expression and purification of mouse fibroblast growth factor-21 and its function in adipocyte glucose metabolism. Prog Biochem Biophys 2012, 39:1089-1098.
6. Kharitonenkov A., Wroblewski V.J., Koester A., Chen Y.F., Clutinger C.K., Tigno X.T., et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007, 148:774-781.
7. Lee B.K., Kwon J.S., Kim H.J., Yamamoto S., Lee E.K. Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: process performance, characterization, and in vitro bioactivity. Bioconjug Chem 2007, 18:1728-1734.
8. Mukai Y., Yoshioka Y., Tsutsumi Y. Phage display and PEGylation of therapeutic proteins. Comb Chem High Throughput Screen 2005, 8:145-152.
9. Huang Z., Wang H., Lu M., Sun C., Wu X., Tan Y., et al. A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol. PLoS One 2011, 6:e20669.
10. Ye X., Qi J., Sun G., Ren G., Zhu S., Wu Y., et al. Enhancement of the pharmacological efficacy of FGF-21 by genetic modification and PEGylation. Curr Pharm Biotechnol 2014, 14:1287-1298.
11. Housel A.K., Shaw R.F., Waterbury N.V. Glucose control in patients with type 2 diabetes based on frequency of insulin glargine administration. Diabetes Res Clin Pract 2010, 88:e17-e19.
12. Lepore M., Pampanelli S., Fanelli C., Porcellati F., Bartocci L., Di Vincenzo A., et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000, 49:2142-2148.
13. Owens D.R., Coates P.A., Luzio S.D., Tinbergen J.P., Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000, 23:813-819.
14. Rosenstock J., Schwartz S.L., Clark C.M., Park G.D., Donley D.W., Edwards M.B. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001, 24:631-636.
15. Massi Benedetti M., Humburg E., Dressler A., Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003, 35:189-196.
16. Yki-Järvinen H., Dressler A., Ziemen M. Less nocturnal hypoglycaemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000, 23:1130-1136. HOE 901/300s Study Group.
17. Liu M., Wang W., Yu Y., Hou Y., Ren G., Li D. FGF21 improves glucose uptake and glycogen synthesis of insulin-resistant liver cells. Prog Biochem Biophys 2009, 36:1327-1333.
18. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2009, 32:S62-S67.
19. Barnett A. Dosing of insulin glargine in the treatment of type 2 diabetes. Clin Ther 2007, 29:987-999.
20. Gerich J.E. Physiology of glucose homeostasis. Diabetes Obes Metab 2000, 2:345-350.
21. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009, 32:193-203.
22. Montanya E., Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther 2009, 31:2472-2488.
23. Malmenäs M., Bouchard J.R., Langer J. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8mg or twice-daily exenatide 10μg. Clin Ther 2013, 35:795-807.
24. Diamant M., Van Gaal L., Stranks S., Northrup J., Cao D., Taylor K., et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010, 375:2234-2243.
25. Davies M., Sinnassamy P., Storms F., Gomis R. Insulin glargine-based therapy improves glycaemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Diabetes Res Clin Pract 2008, 79:368-375. AT.LANTUS Study Group.
26. Coskun T., Bina H.A., Schneider M.A., Dunbar J.D., Hu C.C., Chen Y., et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149:6018-6027.
27. Xu J., Lloyd D.J., Hale C., Stanislaus S., Chen M., Sivits G., et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009, 58:250-259.
28. Hecht R., Li Y.S., Sun J., Belouski E., Hall M., Hager T., et al. Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes. PLoS One 2012, 7:e49345.
29. Abuchowski A., McCoy J.R., Palczuk N.C., van Es T., Davis F.F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977, 252:3582-3586.
30. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005, 10:1451-1458.
31. An Q., Lei Y., Jia N., Zhang X., Bai Y., Yi J., et al. Effect of site-directed PEGylation of trichosanthin on its biological activity, immunogenicity, and pharmacokinetics. Biomol Eng 2007, 24:643-649.
32. Kawashima S., Matsuoka T.A., Kaneto H., Tochino Y., Kato K., Yamamoto K., et al. Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice. Biochem Biophys Res Commun 2011, 404:534-540.
33. Gupta D., Kurhe Y., Radhakrishnan M. Antidepressant effects of insulin in streptozotocin induced diabetic mice: modulation of brain serotonin system. Physiol Behav 2014, 129:73-78.
34. Feng X., Jiang Y., Meltzer P., Yen P.M. Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray. Mol Endocrinol 2000, 14:947-955.
35. Lin Z., Tian H., Lam K.S., Lin S., Hoo R.C., Konishi M., et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 2013, 17:779-789.
36. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
37. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003, 112:91-100.
38. Stickel F., Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 2010, 59:1303-1307.
39. Angelico F., Del Ben M., Conti R., Francioso S., Feole K., Fiorello S., et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005, 90:1578-1582.
40. European Diabetes Policy Group A desktop guide to type 2 diabetes mellitus. Diabet Med 1999, 16:716-730.
41. American Diabetes Association Standards of medical care in diabetes -2007. Diabetes Care 2007, 30:S4-S41.
42. Agius L. Targeting hepatic glucokinase in type2 diabetes: weighing the benefits and risks. Diabetes 2009, 58:18-20.
43. Lu L., Seidel C.P., Iwase T., Stevens R.K., Gong Y.Y., Wang X., et al. Suppression of GLUT1; a new strategy to prevent diabetic complications. J Cell Physiol 2013, 228:251-257.
44. Tremblay F., Lavigne C., Jacques H., Marette A. Defective insulin-induced GLUT4 translocation in skeletal muscle of high fat-fed rats is associated with alterations in both Akt/protein kinase B and atypical protein kinaseC (zeta/lambda) activities. Diabetes 2001, 50:1901-1910.
45. Haber B.A., Chin S., Chuang E., Buikhuisen W., Naji A., Taub R. High levels of glucose-6-phosphatase gene and protein expression reflect an adaptive response in proliferating liver and diabetes. J Clin Invest 1995, 95:832-841.
46. He K., Zhang Y., Ye X., Wang W., Cheng R., Liu M., et al. Stability and glucose regulation of FGF21 after modified with arginines. Prog Biochem Biophys 2012, 39:1089-1098.